Center for Cancer Nanotechnology Excellence Focused on Therapy Response

2009 Annual CCNE-TR Symposium

Garry P. Nolan, Ph.D.
Associate Professor, Microbiology and Immunology
Director, Stanford NHLBI Proteomics Center
Stanford University

Dr. Nolan's laboratory at the Stanford University School of Medicine focuses on the analysis of biological events at the single cell level using novel genetic and FACS-based approaches at the intersection of immunology, biochemistry, and cancer. The laboratory studies phospho-protein immune cell and cancer signaling, and other metabolic parameters by analysis of biochemical functions at the single cell in primary cell populations. This includes interrogation of cancer (Cell, 2004) and immune signaling networks in complex cell populations (Science, 2005) and using multiparameter data to stratify signaling maps from patient samples. Dr. Nolan is currently focused on the clinical and commercial development of diagnostics for use in clinical trial studies.

Dr. Nolan received his Ph.D. in Genetics at Stanford University under the mentorship of Leonard and Leonore Herzenberg (co-developers of the Fluorescence Activated Cell Sorter) where he worked on the cloning of CD8 and development of the first single cell reporter gene assays. Dr. Nolan did his postdoctoral work in the laboratory of Nobelist David Baltimore at MIT, where he cloned and characterized the p65 subunit of NFkB, a central molecule in inflammation and cancer biology. While working in the Baltimore lab he co-developed the 293-based retroviral systems that are now a mainstay of retroviral and lentiviral production in research and gene therapy.

Dr. Nolan is a tenured Faculty member in the Department of Microbiology and Immunology at Sanford University. He has published over 130 articles (biochemistry, gene cloning and characterization, virology immunology, transcriptional biology and signaling) and is the holder of over a dozen patents in the biotechnology arena, and was recently honored as one of the top 25 investors at Stanford University. He was the scientific founder, and was Chair of the scientific advisory board of Rigel Pharmaceuticals (a NASDAQ company), was a co-founder of the limited liability company that led to the creation of CellGate, a drug delivery company, and is the scientific Founder and Chairman of the SAB of Nodality, Inc., a venture funded company researching personalized diagnostics based on single cell interrogations of signaling networks in diseased cells.

[ Back ]